A Phase 2 interventional study of Quadrivalent Inactivated Influenza High Dose and COVID-19 mRNA Vaccine (nucleoside modified) in Influenza Immunization and Healthy Volunteers, sponsored by Sanofi Pasteur, a Sanofi Company. Completed at 6 sites in United States. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-12.
Sponsored by Sanofi Pasteur, a Sanofi Company (part of Sanofi) · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 139 studies in Influenza, Human by Sanofi — 4 open to participants now, 6 under way, 1 of them phase 3. Influenza, Human · Sanofi.
Among the 139 studies in Influenza, Human by Sanofi, this one is the 63rd largest by enrollment of the 126 interventional ones that give a count, is one of 4 that started in 2021, is one of 34 in phase 2, and was the 107th registered.
2,360 studies on the registry are indexed under Influenza, Human; 185 are open to participants now.
Browse Influenza, Human studies →4 of the 139 studies in Influenza, Human by Sanofi are open now, in 3 countries. Recruiting first, the newest first:
Sanofi · Sites in Poland
Ages 60+ · Healthy volunteers
Sanofi · Sites in Korea, Republic of
Ages 65+ · Healthy volunteers
Sanofi · Sites in United States
Ages 18+ · Healthy volunteers
Sanofi · Sites in Korea, Republic of
Ages 65+ · Healthy volunteers
By country, each count listing its studies:
Of the 123 Influenza, Human studies recruiting now, 66 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 68 take healthy volunteers.
This study: 65 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
139 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 47 · Phase 3 35 · Phase 4 33
First in 2003; this study’s year is marked. 4 started in 2021.
This study's enrollment of 306 is above the median of 228 across 1,959 interventional studies indexed under Influenza, Human.
Median enrollment 305 across the 126 interventional studies, 1,001 across the 13 observational. Of the 133 that completed or were terminated, 73 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Sanofi Pasteur, a Sanofi Company, one of the names counted as Sanofi. Under that name alone:
Sanofi Pasteur, a Sanofi Company is the lead sponsor of 374 studies on the registry; 4 are open to participants now.
Of its 94 completed or terminated interventional studies of FDA-regulated products, 73 (78%) have results posted.
2 of the studies in Influenza, Human by Sanofi that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06907511SanofiStudy to Evaluate the Safety and the Immunogenicity of a Second Generation Structurally Designed mRNA Vaccine Candidate Against Pandemic Influenza H5 HA Strain in Healthy Adult Participants Aged 18 Years and Older | 2026-12-01 |
| NCT07516418SanofiStudy of Different Formulations of Vaccines Encoding the RSV Monovalent Antigen or the Flu H5 Antigen in Participants 18 to 49 Years of Age | 2027-04-04 |
Add all 2 to your calendar (.ics) → With an account.
Among the 139 studies in Influenza, Human by Sanofi, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main purpose of this Phase II study was to assess the safety and immunogenicity of a dose of Fluzone High-Dose (HD) Quadrivalent vaccine and a third dose or booster dose of Moderna coronavirus disease 19 (COVID-19) vaccine administered concomitantly or singly in adults 65 years of age and older having received their second dose of the 2-dose schedule of Moderna COVID-19 vaccine at least 5 months before enrollment in the study.
Participants were in the study for 6 months (approximately 180 days).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received an injection of 0.7 milliliters (mL), fluzone HD quadrivalent influenza vaccine, co-administered with 0.5 mL COVID-19 vaccine, intramuscularly (IM) on Day 1.
Biological: Quadrivalent Inactivated Influenza High Dose · Biological: COVID-19 mRNA Vaccine (nucleoside modified)
Participants received a single injection of 0.7 mL fluzone HD quadrivalent influenza vaccine, IM on Day 1.
Biological: Quadrivalent Inactivated Influenza High Dose
Participants received a single injection of 0.5 mL COVID-19 mRNA Vaccine, IM on Day 1.
Biological: COVID-19 mRNA Vaccine (nucleoside modified)
Sterile suspension for injection in a pre-filled syringe Intramuscular injection
Also known as: Fluzone HD Quadrivalent vaccine
Sterile suspension (white to off-white) in multidose vial Intramuscular injection
Also known as: Moderna COVID-19 Vaccine (mRNA-1273 vaccine)
Number of Participants With Immediate Unsolicited Adverse Events (AEs)
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An unsolicited AE was an observed AE that did not fulfill the conditions prelisted in the case report form (CRF) in terms of diagnosis and onset window post-vaccination. All participants were observed for 30 minutes after vaccination, and any unsolicited AEs that occurred during that time were recorded as immediate unsolicited AEs in the CRF. Reported AEs for each arm were presented as pre-specified in the study protocol.
Time frame: Within 30 minutes post vaccination
Number of Participants With Solicited Injection Site Reactions
A solicited reaction (SR) was an "expected" adverse reaction (sign or symptom) observed and reported under the conditions (nature and onset) pre-listed in the protocol and CRF. Solicited injection site reactions included injection site pain, axillary swelling and tenderness, injection site erythema, injection site swelling, injection site induration, and injection site bruising. Reported AEs for each arm were presented as pre-specified in the study protocol.
Time frame: Within 7 days post-vaccination
Number of Participants With Solicited Systemic Reactions
A SR was an "expected" adverse reaction (sign or symptom) observed and reported under the conditions (nature and onset) prelisted (i.e., solicited) in the protocol and CRF. Solicited systemic reactions included fever, headache, malaise, myalgia, arthralgia, shivering, fatigue, nausea and vomiting. Reported AEs for each arm were presented as pre-specified in the study protocol.
Time frame: Within 7 days post-vaccination
Number of Participants With Unsolicited Adverse Events
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An unsolicited AE was an observed AE that did not fulfill the conditions prelisted in the CRF in terms of diagnosis and/or onset window post-vaccination. Reported AEs for each arm were presented as pre-specified in the study protocol.
Time frame: Within 21 days post-vaccination
Number of Participants With Serious Adverse Events (SAEs) and Adverse Event of Special Interest (AESIs)
An SAE was any untoward medical occurrence that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event. AESIs was defined as one of scientific and medical concern specific to the sponsor's study intervention or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor was done. Reported AEs for each arm were presented as pre-specified in the study protocol.
Time frame: From Day 1 up to 6 months post-vaccination
Number of Participants With Medically Attended Adverse Events (MAAEs)
A MAAE was a new onset or a worsening of a condition that prompted the participant or participant's parent/legally acceptable representative to seek unplanned medical advice at a physician's office or emergency department including medical advice seeking during the study visit or routine medical care. Reported AEs for each arm were presented as pre-specified in the study protocol.
Time frame: From Day 1 up to 6 months post-vaccination
Geometric Mean Titers (GMTs) of Influenza Vaccine and COVID-19 Vaccine Antibodies at Day 1
GMTs of anti-influenza and anti-COVID-19 antibodies were measured using hemagglutination inhibition (HAI) assay for 4 influenza virus strains: A/H1N1, A/H3N2, B/Yamagata, and B/Victoria. Titers were expressed in terms of 1/dilution.
Time frame: Day 1 (pre-vaccination)
Geometric Mean Titers (GMTs) of Influenza Vaccine and COVID-19 Vaccine Antibodies at Day 22
GMTs of anti-influenza and anti-COVID-19 antibodies were measured using HAI assay for 4 influenza virus strains: A/H1N1, A/H3N2, B/Yamagata, and B/Victoria. Titers were expressed in terms of 1/dilution.
Time frame: Day 22 (post-vaccination)
Geometric Mean Titers Ratio (GMTR) of Influenza Vaccine and COVID-19 Vaccine Antibodies
GMTs of anti-influenza and anti-COVID-19 antibodies were measured using HAI assay for 4 influenza virus strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata. GMTRs were calculated as the ratio of GMTs post-vaccination (on Day 22) and pre-vaccination (on Day 1) i.e., Day 22/Day 01.
Time frame: Day 1 (pre-vaccination) and Day 22 (post-vaccination)
Percentage of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution)
Anti-influenza and anti-COVID 19 antibodies were measured using HAI assay method for 4 influenza virus strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata. Percentage of participants with HAI titers \>=10 (1/dilution) are reported in the outcome measure.
Time frame: Day 1 (pre-vaccination)
Percentage of Participants With Antibody Titers Greater Than or Equal to (>=)10 (1/Dilution)
Anti-influenza and anti-COVID 19 antibodies were measured using HAI assay method for 4 influenza virus strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata. Percentage of participants with HAI titers \>=10 (1/dilution) are reported in the outcome measure.
Time frame: Day 22 (post-vaccination)
Percentage of Participants Achieving Seroconversion Against Influenza and COVID-19 Virus Antigens
Anti-influenza and anti-COVID-19 antibodies were measured by HAI assay for 4 influenza virus strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata. Seroconversion was defined as either a pre-vaccination HAI titer less than (\<)10 (1/dilution) and a post-vaccination titer \>=40 (1/dilution) or a pre-vaccination titer \>=10 (1/dilution) and a \>= four-fold increase in post-vaccination titer at Day 22.
Time frame: Day 22 (post-vaccination)
Percentage of Participants With Antibody Titers >=40 (1/Dilution)
Anti-influenza and anti-COVID 19 antibodies were measured using HAI assay method for 4 influenza virus strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata. Percentage of participants with HAI titers \>=40 (1/dilution) are reported in the outcome measure.
Time frame: Day 1 (pre-vaccination)
Percentage of Participants With Antibody Titers >=40 (1/Dilution)
Anti-influenza and anti-COVID 19 antibodies were measured using HAI assay method for 4 influenza virus strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata. Percentage of participants with HAI titers \>=40 (1/dilution) are reported in the outcome measure.
Time frame: Day 22 (post-vaccination)
Geometric Mean Concentration (GMC) of Anti-S Binding Immunoglobulin G (IgG) Antibodies
GMCs of Anti-S binding IgG antibodies were assessed using enzyme-linked immunosorbent assay (ELISA) method and were measured in binding antibody units/milliliter (BAU/mL).
Time frame: Day 1 (pre-vaccination)
Geometric Mean Concentration (GMC) of Anti-S Binding Immunoglobulin G (IgG) Antibodies
GMCs of Anti-S binding IgG antibodies were assessed using ELISA method and were measured in BAU/mL.
Time frame: Day 22 (post-vaccination)
Geometric Mean Concentration Ratio (GMCR) of Anti-S Binding IgG Antibodies
GMCs of Anti-S binding IgG antibodies were assessed using ELISA method. GMCR was calculated as the ratio of GMC post-vaccination (on Day 22) and pre-vaccination (on Day 1) i.e., Day 22/Day 01.
Time frame: Day 1 (pre-vaccination) and Day 22 (post-vaccination)
Percentage of Participants With >=2-Fold and >=4-Fold Rise in Anti-S Binding IgG Antibodies
Percentage of participants with \>=2-fold and \>=4-fold rise in Anti-S binding IgG antibodies at Day 22 (post-vaccination) are reported in this outcome measure. Percentage of participants with \>=2-fold rise are those for whom the computed value at Day 22 was \*2 compared to the computed value at Day 1 and percentage of participants with \>=4-fold rise are those for whom the computed value at Day 22 was \*4 compared to the computed value at Day 1.
Time frame: Day 22 (post-vaccination)
The study was conducted at 6 sites in the United States. A total of 306 participants were enrolled between 16 July 2021 to 05 August 2021.
| Milestone | Group 1: Fluzone High-Dose (HD) Quadrivalent Influenza Vaccine and COVID-19 Vaccine | Group 2: Fluzone HD Quadrivalent Influenza Vaccine | Group 3: COVID-19 Vaccine |
|---|---|---|---|
| Started | 100 | 101 | 105 |
| Safety analysis set (safas) | 100 | 92 | 104 |
| Completed | 99 | 89 | 105 |
| Not completed | 1 | 12 | 0 |
| Withdrew: Protocol deviation | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 10 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 |
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An unsolicited AE was an observed AE that did not fulfill the conditions prelisted in the case report form (CRF) in terms of diagnosis and onset window post-vaccination. All participants were observed for 30 minutes after vaccination, and any unsolicited AEs that occurred during that time were recorded as immediate unsolicited AEs in the CRF. Reported AEs for each arm were presented as pre-specified in the study protocol.
| Participants | Group 1: Fluzone HD Quadrivalent Influenza Vaccine and COVID-19 Vaccine | Group 2: Fluzone HD Quadrivalent Influenza Vaccine | Group 3: COVID-19 Vaccine |
|---|---|---|---|
| Number of Participants With Immediate Unsolicited Adverse Events (AEs) | 1 | 1 | 0 |
A solicited reaction (SR) was an "expected" adverse reaction (sign or symptom) observed and reported under the conditions (nature and onset) pre-listed in the protocol and CRF. Solicited injection site reactions included injection site pain, axillary swelling and tenderness, injection site erythema, injection site swelling, injection site induration, and injection site bruising. Reported AEs for each arm were presented as pre-specified in the study protocol.
| Participants | Group 1: Fluzone HD Quadrivalent Influenza Vaccine and COVID-19 Vaccine | Group 2: Fluzone HD Quadrivalent Influenza Vaccine | Group 3: COVID-19 Vaccine |
|---|---|---|---|
| Injection site pain | 82 | 54 | 92 |
| Axillary swelling | 2 | 2 | 1 |
| Axillary tenderness | 3 | 3 | 3 |
| Injection site erythema | 22 | 10 | 32 |
| Injection site swelling | 15 | 6 | 27 |
| Injection site induration | 12 | 3 | 22 |
| Injection site bruising | 7 | 0 | 4 |
A SR was an "expected" adverse reaction (sign or symptom) observed and reported under the conditions (nature and onset) prelisted (i.e., solicited) in the protocol and CRF. Solicited systemic reactions included fever, headache, malaise, myalgia, arthralgia, shivering, fatigue, nausea and vomiting. Reported AEs for each arm were presented as pre-specified in the study protocol.
| Participants | Group 1: Fluzone HD Quadrivalent Influenza Vaccine and COVID-19 Vaccine | Group 2: Fluzone HD Quadrivalent Influenza Vaccine | Group 3: COVID-19 Vaccine |
|---|---|---|---|
| Fever | 12 | 1 | 12 |
| Headache | 52 | 18 | 55 |
| Malaise | 46 | 13 | 59 |
| Myalgia | 50 | 20 | 64 |
| Arthralgia | 24 | 8 | 27 |
| Shivering | 32 | 6 | 22 |
| Fatigue | 62 | 26 | 73 |
| Nausea | 32 | 5 | 27 |
| Vomiting | 4 | 3 | 1 |
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An unsolicited AE was an observed AE that did not fulfill the conditions prelisted in the CRF in terms of diagnosis and/or onset window post-vaccination. Reported AEs for each arm were presented as pre-specified in the study protocol.
| Participants | Group 1: Fluzone HD Quadrivalent Influenza Vaccine and COVID-19 Vaccine | Group 2: Fluzone HD Quadrivalent Influenza Vaccine | Group 3: COVID-19 Vaccine |
|---|---|---|---|
| Number of Participants With Unsolicited Adverse Events | 17 | 11 | 15 |
An SAE was any untoward medical occurrence that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event. AESIs was defined as one of scientific and medical concern specific to the sponsor's study intervention or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor was done. Reported AEs for each arm were presented as pre-specified in the study protocol.
| Participants | Group 1: Fluzone HD Quadrivalent Influenza Vaccine and COVID-19 Vaccine | Group 2: Fluzone HD Quadrivalent Influenza Vaccine | Group 3: COVID-19 Vaccine |
|---|---|---|---|
| SAEs | 2 | 0 | 3 |
| AESIs | 1 | 0 | 1 |
A MAAE was a new onset or a worsening of a condition that prompted the participant or participant's parent/legally acceptable representative to seek unplanned medical advice at a physician's office or emergency department including medical advice seeking during the study visit or routine medical care. Reported AEs for each arm were presented as pre-specified in the study protocol.
| Participants | Group 1: Fluzone HD Quadrivalent Influenza Vaccine and COVID-19 Vaccine | Group 2: Fluzone HD Quadrivalent Influenza Vaccine | Group 3: COVID-19 Vaccine |
|---|---|---|---|
| Number of Participants With Medically Attended Adverse Events (MAAEs) | 10 | 6 | 17 |
GMTs of anti-influenza and anti-COVID-19 antibodies were measured using hemagglutination inhibition (HAI) assay for 4 influenza virus strains: A/H1N1, A/H3N2, B/Yamagata, and B/Victoria. Titers were expressed in terms of 1/dilution.
| titers | Group 1: Fluzone HD Quadrivalent Influenza Vaccine and COVID-19 Vaccine | Group 2: Fluzone HD Quadrivalent Influenza Vaccine | Group 3: COVID-19 Vaccine |
|---|---|---|---|
| A/H1N1: Pre-vaccination | 55.8 (44.2 to 70.4) | 45.5 (34.7 to 59.7) | 49.7 (37.7 to 65.4) |
| A/H3N2: Pre-vaccination | 95.0 (77.5 to 116) | 85.4 (66.3 to 110) | 80.3 (63.1 to 102) |
| B/Yamagata: Pre-vaccination | 221 (178 to 274) | 204 (159 to 262) | 203 (163 to 252) |
| B/Victoria: Pre-vaccination | 163 (137 to 194) | 155 (127 to 190) | 165 (136 to 201) |
GMTs of anti-influenza and anti-COVID-19 antibodies were measured using HAI assay for 4 influenza virus strains: A/H1N1, A/H3N2, B/Yamagata, and B/Victoria. Titers were expressed in terms of 1/dilution.
| titers | Group 1: Fluzone HD Quadrivalent Influenza Vaccine and COVID-19 Vaccine | Group 2: Fluzone HD Quadrivalent Influenza Vaccine | Group 3: COVID-19 Vaccine |
|---|---|---|---|
| A/H1N1: Post-vaccination | 363 (276 to 476) | 366 (272 to 491) | 41.2 (31.4 to 54.2) |
| A/H3N2: Post-vaccination | 286 (233 to 352) | 315 (257 to 386) | 76.5 (61.1 to 95.8) |
| B/Yamagata: Post-vaccination | 429 (350 to 525) | 471 (378 to 588) | 198 (160 to 243) |
| B/Victoria: Post-vaccination | 377 (325 to 438) | 390 (327 to 465) | 176 (146 to 212) |
GMTs of anti-influenza and anti-COVID-19 antibodies were measured using HAI assay for 4 influenza virus strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata. GMTRs were calculated as the ratio of GMTs post-vaccination (on Day 22) and pre-vaccination (on Day 1) i.e., Day 22/Day 01.
| ratio | Group 1: Fluzone HD Quadrivalent Influenza Vaccine and COVID-19 Vaccine | Group 2: Fluzone HD Quadrivalent Influenza Vaccine | Group 3: COVID-19 Vaccine |
|---|---|---|---|
| A/H1N1 | 6.35 (4.88 to 8.26) | 8.10 (6.09 to 10.8) | 0.868 (0.821 to 0.917) |
| A/H3N2 | 3.06 (2.54 to 3.70) | 3.54 (2.82 to 4.45) | 0.940 (0.870 to 1.01) |
| B/Yamagata | 1.94 (1.68 to 2.23) | 2.27 (1.84 to 2.79) | 0.983 (0.918 to 1.05) |
| B/Victoria | 2.27 (1.96 to 2.63) | 2.44 (2.01 to 2.96) | 1.05 (0.972 to 1.14) |
Anti-influenza and anti-COVID 19 antibodies were measured using HAI assay method for 4 influenza virus strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata. Percentage of participants with HAI titers \>=10 (1/dilution) are reported in the outcome measure.
| percentage of participants | Group 1: Fluzone HD Quadrivalent Influenza Vaccine and COVID-19 Vaccine | Group 2: Fluzone HD Quadrivalent Influenza Vaccine | Group 3: COVID-19 Vaccine |
|---|---|---|---|
| A/H1N1: Pre-vaccination | 97.0 (91.4 to 99.4) | 94.5 (87.6 to 98.2) | 91.1 (83.8 to 95.8) |
| A/H3N2: Pre-vaccination | 100 (96.3 to 100) | 98.9 (94.0 to 100) | 99.0 (94.6 to 100) |
| B/Yamagata: Pre-vaccination | 100 (96.3 to 100) | 100 (96.0 to 100) | 99.0 (94.6 to 100) |
| B/Victoria: Pre-vaccination | 100 (96.3 to 100) | 100 (96.0 to 100) | 100 (96.4 to 100) |
Anti-influenza and anti-COVID 19 antibodies were measured using HAI assay method for 4 influenza virus strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata. Percentage of participants with HAI titers \>=10 (1/dilution) are reported in the outcome measure.
| percentage of participants | Group 1: Fluzone HD Quadrivalent Influenza Vaccine and COVID-19 Vaccine | Group 2: Fluzone HD Quadrivalent Influenza Vaccine | Group 3: COVID-19 Vaccine |
|---|---|---|---|
| A/H1N1: Post-vaccination | 100 (96.3 to 100) | 100 (95.8 to 100) | 91.2 (83.9 to 95.9) |
| A/H3N2: Post-vaccination | 100 (96.3 to 100) | 100 (95.8 to 100) | 99.0 (94.7 to 100) |
| B/Yamagata: Post-vaccination | 100 (96.3 to 100) | 100 (95.8 to 100) | 99.0 (94.7 to 100) |
| B/Victoria: Post-vaccination | 100 (96.3 to 100) | 100 (95.8 to 100) | 100 (96.4 to 100) |
Anti-influenza and anti-COVID-19 antibodies were measured by HAI assay for 4 influenza virus strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata. Seroconversion was defined as either a pre-vaccination HAI titer less than (\<)10 (1/dilution) and a post-vaccination titer \>=40 (1/dilution) or a pre-vaccination titer \>=10 (1/dilution) and a \>= four-fold increase in post-vaccination titer at Day 22.
| percentage of participants | Group 1: Fluzone HD Quadrivalent Influenza Vaccine and COVID-19 Vaccine | Group 2: Fluzone HD Quadrivalent Influenza Vaccine | Group 3: COVID-19 Vaccine |
|---|---|---|---|
| A/H1N1 | 68.8 (58.5 to 77.8) | 72.1 (61.4 to 81.2) | 0.0 (0.0 to 3.6) |
| A/H3N2 | 43.8 (33.6 to 54.3) | 47.7 (36.8 to 58.7) | 0.0 (0.0 to 3.6) |
| B/Yamagata | 17.7 (10.7 to 26.8) | 20.9 (12.9 to 31.0) | 1.0 (0.0 to 5.4) |
| B/Victoria | 30.2 (21.3 to 40.4) | 24.4 (15.8 to 34.9) | 1.0 (0.0 to 5.4) |
Anti-influenza and anti-COVID 19 antibodies were measured using HAI assay method for 4 influenza virus strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata. Percentage of participants with HAI titers \>=40 (1/dilution) are reported in the outcome measure.
| percentage of participants | Group 1: Fluzone HD Quadrivalent Influenza Vaccine and COVID-19 Vaccine | Group 2: Fluzone HD Quadrivalent Influenza Vaccine | Group 3: COVID-19 Vaccine |
|---|---|---|---|
| A/H1N1: Pre-vaccination | 65.7 (55.4 to 74.9) | 56.0 (45.2 to 66.4) | 59.4 (49.2 to 69.1) |
| A/H3N2: Pre-vaccination | 83.8 (75.1 to 90.5) | 79.1 (69.3 to 86.9) | 77.2 (67.8 to 85.0) |
| B/Yamagata: Pre-vaccination | 97.0 (91.4 to 99.4) | 90.1 (82.1 to 95.4) | 96.0 (90.2 to 98.9) |
| B/Victoria: Pre-vaccination | 99.0 (94.5 to 100) | 94.5 (87.6 to 98.2) | 95.0 (88.8 to 98.4) |
Anti-influenza and anti-COVID 19 antibodies were measured using HAI assay method for 4 influenza virus strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata. Percentage of participants with HAI titers \>=40 (1/dilution) are reported in the outcome measure.
| percentage of participants | Group 1: Fluzone HD Quadrivalent Influenza Vaccine and COVID-19 Vaccine | Group 2: Fluzone HD Quadrivalent Influenza Vaccine | Group 3: COVID-19 Vaccine |
|---|---|---|---|
| A/H1N1: Post-vaccination | 94.8 (88.4 to 98.3) | 95.3 (88.5 to 98.7) | 53.9 (43.8 to 63.8) |
| A/H3N2: Post-vaccination | 96.9 (91.2 to 99.4) | 100 (95.8 to 100) | 72.5 (62.8 to 80.9) |
| B/Yamagata: Post-vaccination | 100 (96.3 to 100) | 98.8 (93.7 to 100) | 96.1 (90.3 to 98.9) |
| B/Victoria: Post-vaccination | 100 (96.3 to 100) | 100 (95.8 to 100) | 96.1 (90.3 to 98.9) |
GMCs of Anti-S binding IgG antibodies were assessed using enzyme-linked immunosorbent assay (ELISA) method and were measured in binding antibody units/milliliter (BAU/mL).
| BAU/mL | Group 1: Fluzone HD Quadrivalent Influenza Vaccine and COVID-19 Vaccine | Group 2: Fluzone HD Quadrivalent Influenza Vaccine | Group 3: COVID-19 Vaccine |
|---|---|---|---|
| Geometric Mean Concentration (GMC) of Anti-S Binding Immunoglobulin G (IgG) Antibodies | 565 (479 to 666) | 462 (382 to 560) | 552 (461 to 662) |
GMCs of Anti-S binding IgG antibodies were assessed using ELISA method and were measured in BAU/mL.
| BAU/mL | Group 1: Fluzone HD Quadrivalent Influenza Vaccine and COVID-19 Vaccine | Group 2: Fluzone HD Quadrivalent Influenza Vaccine | Group 3: COVID-19 Vaccine |
|---|---|---|---|
| Geometric Mean Concentration (GMC) of Anti-S Binding Immunoglobulin G (IgG) Antibodies | 7634 (6445 to 9042) | 395 (311 to 502) | 7904 (6883 to 9077) |
GMCs of Anti-S binding IgG antibodies were assessed using ELISA method. GMCR was calculated as the ratio of GMC post-vaccination (on Day 22) and pre-vaccination (on Day 1) i.e., Day 22/Day 01.
| ratio | Group 1: Fluzone HD Quadrivalent Influenza Vaccine and COVID-19 Vaccine | Group 2: Fluzone HD Quadrivalent Influenza Vaccine | Group 3: COVID-19 Vaccine |
|---|---|---|---|
| Geometric Mean Concentration Ratio (GMCR) of Anti-S Binding IgG Antibodies | 13.7 (11.2 to 16.8) | 0.875 (0.745 to 1.03) | 14.2 (12.0 to 16.9) |
Percentage of participants with \>=2-fold and \>=4-fold rise in Anti-S binding IgG antibodies at Day 22 (post-vaccination) are reported in this outcome measure. Percentage of participants with \>=2-fold rise are those for whom the computed value at Day 22 was \*2 compared to the computed value at Day 1 and percentage of participants with \>=4-fold rise are those for whom the computed value at Day 22 was \*4 compared to the computed value at Day 1.
| percentage of participants | Group 1: Fluzone HD Quadrivalent Influenza Vaccine and COVID-19 Vaccine | Group 2: Fluzone HD Quadrivalent Influenza Vaccine | Group 3: COVID-19 Vaccine |
|---|---|---|---|
| >= 2-fold rise | 97.9 (92.7 to 99.7) | 3.5 (0.7 to 9.9) | 98.0 (93.1 to 99.8) |
| >= 4-fold rise | 92.7 (85.6 to 97.0) | 2.3 (0.3 to 8.1) | 95.1 (88.9 to 98.4) |
Collected over Unsolicited AEs were collected from Day 1 up to 21 days post-vaccination. SR data were collected up to 7 days post-vaccination. SAE data were collected from Day 1 up to 6 months post-vaccination. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group 1: Fluzone High-Dose (HD) Quadrivalent Influenza Vaccine and COVID-19 Vaccine | 0/100 (0%) | 2/100 (2%) | 94/100 (94%) |
| Group 2: Fluzone HD Quadrivalent Influenza Vaccine | 0/92 (0%) | 0/92 (0%) | 65/92 (70.7%) |
| Group 3: COVID-19 Vaccine | 0/104 (0%) | 3/104 (2.9%) | 100/104 (96.2%) |
| Event | Group 1: Fluzone High-Dose (HD) Quadrivalent Influenza Vaccine and COVID-19 Vaccine | Group 2: Fluzone HD Quadrivalent Influenza Vaccine | Group 3: COVID-19 Vaccine |
|---|---|---|---|
| Myocardial InfarctionCardiac disorders | 1/100 | 0/92 | 0/104 |
| Papillary Thyroid CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/100 | 0/92 | 0/104 |
| Thyroid MassEndocrine disorders | 0/100 | 0/92 | 1/104 |
| Diabetic GastroparesisGastrointestinal disorders | 0/100 | 0/92 | 1/104 |
| Pelvic FractureInjury, poisoning and procedural complications | 0/100 | 0/92 | 1/104 |
| ExostosisMusculoskeletal and connective tissue disorders | 0/100 | 0/92 | 1/104 |
| Event | Group 1: Fluzone High-Dose (HD) Quadrivalent Influenza Vaccine and COVID-19 Vaccine | Group 2: Fluzone HD Quadrivalent Influenza Vaccine | Group 3: COVID-19 Vaccine |
|---|---|---|---|
| Injection Site PainGeneral disorders | 82/100 | 54/92 | 92/104 |
| FatigueGeneral disorders | 62/100 | 26/92 | 73/104 |
| MyalgiaMusculoskeletal and connective tissue disorders | 50/100 | 20/92 | 64/104 |
| MalaiseGeneral disorders | 46/100 | 13/92 | 59/104 |
| HeadacheNervous system disorders | 52/100 | 18/92 | 55/104 |
| NauseaGastrointestinal disorders | 32/100 | 6/92 | 27/104 |
| ChillsGeneral disorders | 32/100 | 6/92 | 22/104 |
| Injection Site ErythemaGeneral disorders | 22/100 | 10/92 | 32/104 |
| Injection Site SwellingGeneral disorders | 15/100 | 6/92 | 27/104 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 24/100 | 8/92 | 27/104 |
Analysis was performed on all randomized participants.
| Age, Continuous(years) | Group 1: Fluzone HD Quadrivalent Influenza Vaccine and COVID-19 Vaccine | Group 2: Fluzone HD Quadrivalent Influenza Vaccine | Group 3: COVID-19 Vaccine | Total |
|---|---|---|---|---|
| Mean | 71.3 ± 4.76 | 71.7 ± 5.16 | 72.0 ± 4.89 | 71.7 ± 4.93 |
| Sex: Female, Male(Participants) | Group 1: Fluzone HD Quadrivalent Influenza Vaccine and COVID-19 Vaccine | Group 2: Fluzone HD Quadrivalent Influenza Vaccine | Group 3: COVID-19 Vaccine | Total |
|---|---|---|---|---|
| Female | 55 | 54 | 63 | 172 |
| Male | 45 | 47 | 42 | 134 |
| Race (NIH/OMB)(Participants) | Group 1: Fluzone HD Quadrivalent Influenza Vaccine and COVID-19 Vaccine | Group 2: Fluzone HD Quadrivalent Influenza Vaccine | Group 3: COVID-19 Vaccine | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 2 | 0 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 2 | 3 |
| Black or African American | 1 | 4 | 0 | 5 |
| White | 94 | 95 | 103 | 292 |
| More than one race | 1 | 1 | 0 | 2 |
| Unknown or Not Reported | 2 | 0 | 0 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from Jul 2021 to primary completion in Feb 2022, 6 months.
Results were first posted in Dec 2022, 10 months after primary completion.
Of 86 industry-sponsored phase 2 interventional studies under Influenza, Human, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 14. This study's 6 months is below that.
Counting every sponsor, half of 122 studies reached it within 10 months; a quarter within 5 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: mRNA COVID-19 Vaccine
Sanofi Pasteur, a Sanofi Company →